These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24574715)

  • 1. Evolution of hepatitis B management in kidney transplantation.
    Yap DY; Chan TM
    World J Gastroenterol; 2014 Jan; 20(2):468-74. PubMed ID: 24574715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
    Ruhi Ç; Süleymanlar İ; Koçak H; Dinçkan A; Ersoy F; Süleymanlar G
    Exp Clin Transplant; 2015 Feb; 13(1):35-40. PubMed ID: 25019317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus infection and renal transplantation.
    Tsai MC; Chen YT; Chien YS; Chen TC; Hu TH
    World J Gastroenterol; 2010 Aug; 16(31):3878-87. PubMed ID: 20712048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.
    Yang YW; Lee CY; Hu RH; Lee PH; Tsai MK
    Clin Exp Nephrol; 2014 Feb; 18(1):144-50. PubMed ID: 23605388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with hepatitis B in special populations.
    Cholongitas E; Tziomalos K; Pipili C
    World J Gastroenterol; 2015 Feb; 21(6):1738-48. PubMed ID: 25684938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of chronic viral hepatitis before and after renal transplantation.
    Gane E; Pilmore H
    Transplantation; 2002 Aug; 74(4):427-37. PubMed ID: 12352899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
    Ahn HJ; Kim MS; Kim YS; Kim SI; Huh KH; Ju MK; Ahn SH; Han KH
    J Med Virol; 2007 Nov; 79(11):1655-63. PubMed ID: 17854044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States.
    Reddy PN; Sampaio MS; Kuo HT; Martin P; Bunnapradist S
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1481-7. PubMed ID: 21566110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of viral hepatitis in solid organ transplantation].
    Mikolašević I; Sladoje-Martinović B; Orlić L; Milić S; Lukenda V; Župan Ž; Štimac D; Rački S
    Acta Med Croatica; 2014 Apr; 68(2):151-9. PubMed ID: 26012153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis B in patients with chronic kidney disease.
    Pipili CL; Papatheodoridis GV; Cholongitas EC
    Kidney Int; 2013 Nov; 84(5):880-5. PubMed ID: 23783238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B in Solid-Organ Transplant Procedures Other Than Liver.
    Halegoua-De Marzio D; Fenkel JM; Doria C
    Exp Clin Transplant; 2017 Apr; 15(2):130-137. PubMed ID: 28338458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hepatitis B after renal transplantation: an update.
    Fabrizi F; Lunghi G; Poordad FF; Martin P
    J Nephrol; 2002; 15(2):113-22. PubMed ID: 12018626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.